Immatics' IMA402 achieves 32% confirmed response rate in PRAME-high melanoma trial patients

Bitget2026/10/24 06:30

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Immatics announced updated early-stage trial results showing durable tumor responses across advanced solid cancers with IMA402 bispecific therapy and IMA203CD8 cell therapy.
IMA402 showed favorable tolerability, supporting development across multiple cancers; results will be presented at the 2026 ESMO meeting.
IMA203CD8 results were presented at ESMO, showing durable activity with manageable safety, including in heavily pretreated gynecologic cancers.
Development plans include IMA402 combination studies with initial lung cancer data expected in 2027.
A pediatric cancer trial of IMA203CD8 is planned to begin in the first half of 2027, supporting broader development across PRAME-positive cancers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immatics NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610240230PRIMZONEFULLFEED1001279570) on October 24, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Immatics' IMA402 achieves 32% confirmed response rate in PRAME-high melanoma trial patients

You may also like

Crypto prices